top of page

Free Biopharma Daily Stock Updates - 03/18/22

$XBI $92.16 | +2.9%

 

Covid Updates

$MRNA +6.3% MODERNA SUBMITS AMENDMENT TO THE EMERGENCY USE AUTHORIZATION FOR AN ADDITIONAL BOOSTER DOSE OF ITS COVID-19 VACCINE IN THE U.S.



Pipeline Updates

$MRNS +16.4% Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder. source


$ONCY -1.2% Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting.


$SRNE +1.2% Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 (SEMDEXA™) Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management Supporting the Potential for.


$ASLN +7.2% ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab Proof-of-Concept Study in Atopic Dermatitis for Oral Presentation at the 2022 American Academy of Dermatology Annual Meeting.


$PLX +12.9% Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease.


$CALT +2.5% Calliditas Therapeutics AB today announced that partner Everest Medicines plans to submit an NDA for NEFECON in China in the second half of 2022.



Business Updates

$ORPH -2.2% Notice of in-court restructuring proceedings of Orphazyme A/S.


 

Posted by DV/FS

0 comments

Comments


bottom of page